Showing 9581-9590 of 20338 results for "".
- Inebilizumab vs Low-Dose Rituximab In NMOSDhttps://reachmd.com/news/inebilizumab-low-dose-rituximab-nmosd/2486946/Key Takeaways In NMOSD, inebilizumab was associated with fewer relapses and more favorable relapse-free survival and adjusted relapse burden over 12 months. Relapse-associated EDSS worsening was less frequent, and overall EDSS improvement favored inebi
- Allergan Aesthetics Launches Skin Cancer Awareness Month Initiativehttps://reachmd.com/news/allergan-aesthetics-launches-skin-cancer-awareness-month-initiative/2486944/Allergan Aesthetics, an AbbVie company, launched a charitable initiative for Skin Cancer Awareness Month that will support The Skin Cancer Foundation through its Allē loyalty program. Throughout May, the company will donate $10 to The Skin Cancer Foundation for every new person who joins A
- Darvadstrocel Misses Primary Endpoint in ADMIRE CD II Trialhttps://reachmd.com/news/darvadstrocel-misses-primary-endpoint-in-admire-cd-ii-trial/2486932/Key Takeaways Week-24 combined remission was similar between darvadstrocel and placebo, and the primary endpoint was not met. Key secondary efficacy measures, including clinical remission at week 24 and time to clinical remission, were also similar bet
- CRT-Guided Resuscitation Improves Hierarchical Outcomes in Early Septic Shockhttps://reachmd.com/news/capillary-refill-time-early-septic-shock/2486923/Key Takeaways CRT-PHR was associated with a favorable 28-day hierarchical outcome versus usual care in early septic shock. Early resuscitation under CRT-PHR involved less fluid, more dobutamine use, lower central venous pressure and lactate, and more f
- Quintuple GLP-1R-GIPR-PPAR Agonism Improves Mouse Metabolismhttps://reachmd.com/news/glp-1r-gipr-ppar-agonism-mouse-metabolism/2486919/Key Takeaways In mouse models, a novel “quintuple agonist” combiningGLP-1 and GIP receptor activation with triple PPAR (α/γ/δ) agonism outperformed semaglutide and GLP-1/GIP co-agonism in reducing body weight, food intake, and blood glucose. Safety fin
- RAAS Inhibition vs Calcium Channe Blockade in Pediatric CKDhttps://reachmd.com/news/raas-inhibition-vs-ccb-in-pediatric-ckd/2486907/Key Takeaways First-line RAAS inhibition was associated with fewer kidney replacement therapy events over 2 years than calcium channel blockade. RAAS inhibition was also associated with a lower secondary kidney composite risk and less time with systoli
- Comparative Evidence for IgA Nephropathy Therapies in a Network Meta-Analysishttps://reachmd.com/news/comparative-evidence-for-iga-nephropathy-therapies-in-a-network-meta-analysis/2486909/Key Takeaways Nefecon was associated with the most favorable eGFR slope point estimate and the highest SUCRA ranking, although uncertainty remained. Methylprednisolone showed the largest UPCR reductions versus placebo, while iptacopan and sibeprenlimab
- Luvadaxistat Fails To Improve Cognition in ERUDITE Phase 2 Trialhttps://reachmd.com/news/luvadaxistat-fails-to-improve-cognition-in-erudite-phase-2-trial/2486910/Key Takeaways Neither the 20 mg nor 50 mg dose of luvadaxistat improved the primary cognitive endpoint versus placebo at Day 98. Secondary cognitive, functional, and clinical measures also did not differ significantly from placebo. Adverse eve
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://reachmd.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Analysis: PRS Improves Melanoma Risk Predictionhttps://reachmd.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a